ライフサイエンスコーパス: hepatic-portal

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します

1 ted from the femoral artery and vein and the hepatic, portal, and renal veins to determine total hemo

2 The arterial glucagon levels (ng/l) and the hepatic portal-arterial difference in plasma glucagon (n

3 The arterial glucagon level (ng/l) and the hepatic portal-arterial difference in plasma glucagon (n

4 Arterial glucagon level (ng/l) and the hepatic portal-arterial difference in plasma glucagon (n

5 The arterial plasma glucagon levels and the hepatic portal-arterial difference in plasma glucagon de

6 The arterial glucagon levels and the hepatic portal-arterial difference in plasma glucagon in

7 erial plasma insulin levels (pmol/l) and the hepatic portal-arterial difference in plasma insulin (pm

8 Arterial plasma insulin levels and the hepatic portal-arterial difference in plasma insulin dec

9 The arterial plasma insulin levels and the hepatic portal-arterial difference in plasma insulin inc

10 The hepatic portal-arterial difference in plasma insulin was

11 The hepatic portal-arterial difference in plasma insulin was

12 ned, the insulin and glucagon levels and the hepatic portal-arterial difference remained constant.

13 The insulin and glucagon levels and the hepatic portal-arterial differences remained constant.

14 Hepatic portal ascorbate accumulation was nearly abolish

15 ive agent of schistosomiasis, resides in the hepatic portal circulation of their human host up to 30

16 n distribution in arterial, deep venous, and hepatic portal circulation.

17 anced fructose uptake and transport into the hepatic portal circulation.

18 The biliary ductual ectasia and hepatic portal fibrosis associated with ARPKD have not b

19 ar hyperplasia along with varying degrees of hepatic portal fibrosis that is indistinguishable from t

20 primarily palliative, whereas MLPVB restores hepatic portal flow in patients with EHPVT.

21 that a commitment to life in the endothermic hepatic portal system favored a filiform body form for e

22 choice for the identification of gas in the hepatic portal system in children.

23 Because the hepatic portal system may not be the optimal site for is

24 and IL21R in PBC livers (particularly in the hepatic portal tracks) support a disease mechanism in wh

25 e alveolar edema in the absence of necrosis, hepatic-portal triaditis, mononuclear-cellular infiltrat

26 lycogen synthesis during hyperinsulinemia or hepatic portal vein glucose infusion in vivo.

27 Specifically, it is unlikely that a hepatic portal vein glucose sensor signaling RYGB-induce

28 ch potentially sensing glucose levels in the hepatic portal vein has recently been suggested in a mou

29 luate an alternate method of administration, hepatic portal vein infusion of G207 was performed in a

30 Using a pancreatic clamp, hepatic portal vein insulin delivery was increased three

31 V-AGA) was constructed and injected into the hepatic portal vein of Fabry mice.

32 ic acid, 80 +/- 12% of labeled folate in the hepatic portal vein was unmodified folic acid.

33 Hepatocytes are usually infused into the hepatic portal vein with many cells rapidly cleared by t

34 ntegrity of vagal nerve supply to the liver, hepatic portal vein, and the proximal duodenum provided

35 ecretory bursts at ~5-min intervals into the hepatic portal vein, these pulses being attenuated early

36 Eight dogs underwent combined hepatic/portal vein catheterization and infusion of D4-c

37 7%, ascites was present in 84%, and abnormal hepatic portal venous flow was present in 35%.

38 Hepatic portal venous gas (HPVG) is a rare imaging findi

39 Hepatic portal venous gas (HPVG) is an ominous radiologi

40 nts underwent transjugular liver biopsy with hepatic portal venous gradient (HPVG) measurements.

WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。